UBS cuts Cytokinetics to neutral, sees takeout valuation at $105
https://seekingalpha.com/news/4057887-ubs-cuts-cytokinetics-to-neutral-sees-takeout-valuation-at-105?source=feed_sector_healthcare
Jan 24, 2024 - UBS has downgraded Cytokinetics (CYTK) to neutral, commenting that it believes some of the potential M&A premium has already been baked into the stock’s price. Read more here.
0
U.S. Stocks May See Initial Strength On Upbeat Netflix Results
https://www.rttnews.com/story.aspx?Id=3418794
Jan 24, 2024 - Following the lackluster performance seen in the previous session, stocks are likely to move mostly higher in early trading on Wednesday. Technology stocks may help lead an early advance on Wall Street, as reflected by the 0.9 percent jump by the Nasdaq 100 futures. The upward momentum in the tech sector comes as shares of Netflix (NFLX) are surging by 10.6 percent in pre-market trading.
0
We're pleased to see P&G shares pop on solid quarterly earnings. But don't chase the rally
https://www.cnbc.com/2024/01/23/pg-shares-pop-on-solid-quarterly-earnings-but-do-not-chase-rally.html
Jan 23, 2024 - While sales missed the mark, profitability was solid.
0
Marriott (MAR) Sees Solid 2023 Unit Growth, Signings Grow Y/Y
https://www.zacks.com/stock/news/2214243/marriott-mar-sees-solid-2023-unit-growth-signings-grow-y-y?cid=CS-ZC-FT-analyst_blog|company_news_-_corporate_actions-2214243
Jan 23, 2024 - Marriott (MAR) celebrates a remarkable year in 2023, setting a new record in global signings with a substantial 52% year-over-year increase in organic rooms.
0
A New Way to See Your Climate Anxiety
https://www.wired.com/story/a-new-way-to-see-your-climate-anxiety/
Jan 22, 2024 - The climate crisis has become a mental health crisis. But eco-anxiety isn’t necessarily a pathology.
0
Takeaways from Davos: Business leaders see no recession in 2024, and few want to talk about Israel
https://www.cnbc.com/2024/01/19/takeaways-from-davos-wef-2024-us-recession-ai-china-economy.html
Jan 19, 2024 - The annual World Economic Forum is wrapping up in Davos, Switzerland, and key takeaways include predictions about a U.S. recession and AI.
0
Wall Street Analysts See Alibaba (BABA) as a Buy: Should You Invest?
https://www.zacks.com/stock/news/2212784/wall-street-analysts-see-alibaba-baba-as-a-buy-should-you-invest?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2212784
Jan 19, 2024 - The average brokerage recommendation (ABR) for Alibaba (BABA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
0
The One Part of the Vision Pro That Apple Doesn’t Want You to See
https://www.wired.com/story/one-part-of-apple-vision-pro-apple-doesnt-want-you-to-see/
Jan 18, 2024 - Apple’s latest series of Vision Pro demos carefully obscures one important hardware feature.
0
Stock And Mixed Assets ETFs Attract Record Net Inflows In December While Mutual Funds See Redemptions
https://seekingalpha.com/article/4663622-stock-and-mixed-assets-etfs-attract-record-net-inflows-in-december?source=feed_tag_etf_portfolio_strategy
Jan 18, 2024 - Mutual fund investors withdrew $86.0 billion in December, while money market funds saw net inflows. Click here to read our most recent report.
0
Lilly, Novo Nordisk diabetes drugs see price raises - report
https://seekingalpha.com/news/4056146-lilly-novo-nordisk-diabetes-drugs-see-price-raises?source=feed_sector_healthcare
Jan 18, 2024 - Popular diabetes medicines Mounjaro and Ozempic, as well as other drugs, saw list price increases this month. Read more here.
0